Search company, investor...


About EyRIS

EyRIS develops and deploys AI Deep Learning System (DLS) in the healthcare industry. DLS, a machine learning technology, utilizes representation-learning methods with multiple levels of representation to process natural data in their raw form, recognizing the intricate structure in high-dimensional data.

Headquarters Location

60 MacPherson Road Block 1 Siemens Centre #05-08



Missing: EyRIS's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EyRIS's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing EyRIS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EyRIS is included in 1 Expert Collection, including Diabetes.



1,898 items

Latest EyRIS News

Nova MSC Collaborates with AMO and RHAZES to Bring its AI Deep Learning Technology, SELENA+ to Mainstream Adoption

Feb 21, 2022

Intellasia East Asia News 21-Feb-2022 Intellasia | Media OutReach | 12:30 PM Nova MSC signs MoU with AMO and RHAZES that will enable the deployment of its EyRIS' AI-Deep Learning Technology, SELENA+ to more than 1,000 AMO members via RHAZES Telehealth service SELENA+ is capable of detecting up to 3 retinal diseases, principally diabetic retinopathy, glaucoma suspect and age-related macular degeneration EyRIS SELENA+ will also become a gamechanger in first stage diagnostic with the addition of a new algorithm to detect chronic kidney disease (CKD) EyRIS has inked a Research Collaboration Agreement with a specialty centre under the National Healthcare Group (NHG) to develop a new proprietary AI that detects melanoma using a mobile phone camera KUALA LUMPUR, MALAYSIA -  Media OutReach  - 21 February 2022 - Nova MSC Berhad ("Nova MSC" or "the Company"), which is the exclusive distributor of EyRIS Pte Ltd's ("EyRIS") products, has signed a Memorandum of Understanding ("MoU") with the Association of Malaysian Optometrists ("AMO") and Rhazes Consultancy Services Sdn Bhd ("RHAZES"), a tele-pharmacy platform provider, to bring its AI Deep Learning Technology, SELENA+ to mainstream adoption in Malaysia. Under the collaboration, EyRIS' AI deep learning technology, SELENA+, will be deployed to AMO's more than 1,000 members across Malaysia via RHAZES Telehealth. RHAZES Telehealth is Malaysia's first knowledge-based telehealth service provider through its brand Rhazes TeleOpto. EyRIS is 42% owned by novaHEALTH Pte Ltd, which in turn is wholly-owned by Nova MSC. Nova MSC's General Manager, Mr Nazerollnizam Kasim, said, "We are optimistic that the collaboration with both AMO and RHAZES will drive forward the adoption of SELENA+ in Malaysia. During the pandemic, we have seen a rise in telehealth and how it has gradually moved towards mainstream adoption." According to En. Ahmad Fadhullah Fuzai, President of AMO, "The deployment of SELENA+ to AMO's member practices across the country will help to improve the range and quality of our services. This synergistic partnership with Nova will see the launch of SELENA+, and it will be deployed initially in 55 practices across Malaysia through Rhazes' TeleOpto Platform, eventually expanding to the other member practices within a year." SELENA+ is capable of detecting up to 3 retinal diseases, principally diabetic retinopathy, glaucoma suspect and age-related macular degeneration. Early screening and detection of these diseases can significantly reduce vision loss, and in the case of diabetic retinopathy, studies have shown that diabetes-related vision loss can be reduced by up to 47 percent. EyRIS' SELENA+ has been approved for use by the Malaysian Medical Device Authority since 22nd June 2020. Aside from that, there will also be an addition of a new algorithm to detect chronic kidney disease ("CKD") through the same fundus image used by EyRIS' SELENA+ to detect the 3 retinal diseases mentioned earlier. Nova MSC's Group Chief Executive Officer, Mr Lai Teik Kin added, "The addition of this new algorithm will help us to be a gamechanger in the first stage diagnostic, a drive towards being able to implement rapid screening tools to aid early detection for systemic diseases. Our CKD algorithm boasts an 85 percent accuracy rate, and uses of the non-invasive fundus imaging allows results to be generated within 10-15 seconds with ease, speed and accuracy," Mr Lai said. He also pointed out that the recent gold award won by EyRIS at the Techblazer Awards 2021 in the Most Promising Innovation category is a sign of the Group's push to bring world-class technology into the world. The Techblazer Awards is Singapore's highest accolade for technological innovation. The push to deploy SELENA+ into mainstream adoption in healthcare services has seen the availability of its technology in 26 countries. In order to continue to expand the capabilities in disease detection through its cutting-edge AI deep learning technology, EyRIS has inked a Research Collaboration Agreement with a specialty centre under the National Healthcare Group (NHG) to develop a new proprietary AI that detects melanoma using a mobile phone camera. This was facilitated by NHG's Centre for Medical Technologies and Innovations (CMTi). Melanoma is the deadliest form of skin cancer, and early detection is able to increase the 5-year survival rate to 99 percent. With 1 in every 3 cancer diagnoses being skin cancer and the high melanoma incidence rate of 3.4 per 100,000 worldwide, the ability to detect skin cancer early through non-invasive, mobile imaging will contribute to the fight against skin cancer mortality. We are Nova MSC Berhad Established in 2002, Nova MSC Bhd is a Bursa Malaysia ACE Market-listed company, which is involved in four main business pillars namely, healthcare, Digital Government, building automation and virtual construction. We are a leading provider of ready-to-deploy, industry-focused application software and services for both the public and healthcare sectors, with an international track-record. Our products are developed based on our technical knowledge and in-depth understanding of industry demands and the clients' requirements, thereby bringing improved productivity to our customers. For more info, visit:

EyRIS Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EyRIS Rank

EyRIS Frequently Asked Questions (FAQ)

  • Who are EyRIS's competitors?

    Competitors of EyRIS include Viderai.

Compare EyRIS to Competitors

Retinai Logo

Retinai supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence. Its vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as age-related Macular Degeneration, Diabetic Retinopathy, and Glaucoma. Its solutions rely on advances in medical image analysis, opthalmology, and machine learning.

Digital Diagnostics Logo
Digital Diagnostics

Digital Diagnostics is an AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The platform includes two autonomous AI systems, IDx-DR and 3DermSpot. The company was founded in 2010 and is based in Coralville, Iowa.

Eyenuk Logo

Eyenuk is focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and preserving their vision. Using computer vision and image analysis expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology to identify and track the progression of eye diseases including diabetic retinopathy and age-related macular degeneration. The company was founded in 2010 and is based in Woodland Hills, California.


Ophtai develops artificial intelligence-based eye screening and diagnostic software that analyzes retina fundus photos and detects early signs of diabetic retinopathy as well as the risk of glaucoma or AMD. It was founded in 2019 and is based in Villers-Bretonneux, France.


Viderai provides retinal analysis using artificial intelligence to patients. It offers products that help specialists diagnose patients with diseases such as diabetic retinopathy. Its primary clients are ophthalmologists and public healthcare insurance companies. Viderai was founded in 2019 and is based in Ostrava, the Czech Republic.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.